—Significantly greater improvement in the Positive and Negative Symptom Scale was demonstrated in schizophrenia patients treated with SEP-363856, a TAAR1 agonist, compared to placebo—
—Effects on extrapyramidal symptoms, weight and other metabolic parameters were similar in the SEP-363856 and placebo treatment groups—
Looks very interesting. There was 1 cardiac death in the drug cohort.
New England Journal abstract
Oh geez. 
Cardiac deaths are higher among schizophrenics normally I think. Feel bad for the family, but hoping this was just a coincidence rather than being a direct result of the drug. I have high hopes for SEP-363856.
“One patient died from sudden cardiac arrest and was found to have coronary artery disease and pulmonary embolism in an autopsy report, the researchers noted.”